NASDAQ:SHPG - Shire Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$169.89 +0.94 (+0.56 %)
(As of 05/23/2018 06:00 AM ET)
Previous Close$169.89
Today's Range$169.69 - $170.89
52-Week Range$123.73 - $187.58
Volume966,253 shs
Average Volume1.52 million shs
Market Capitalization$51.55 billion
P/E Ratio11.21
Dividend Yield0.62%
Beta1.3

About Shire (NASDAQ:SHPG)

Shire logoShire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SHPG
CUSIPN/A
Phone353-1609-6000

Debt

Debt-to-Equity Ratio0.45
Current Ratio1.14
Quick Ratio0.66

Price-To-Earnings

Trailing P/E Ratio11.21
Forward P/E Ratio11.13
P/E Growth1.34

Sales & Book Value

Annual Sales$15.16 billion
Price / Sales3.41
Cash Flow$22.7430 per share
Price / Cash7.47
Book Value$119.43 per share
Price / Book1.42

Profitability

EPS (Most Recent Fiscal Year)$15.15
Net Income$4.27 billion
Net Margins28.96%
Return on Equity13.60%
Return on Assets6.92%

Miscellaneous

Employees23,044
Outstanding Shares303,950,000

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire declared a semiannual dividend on Friday, February 16th. Investors of record on Friday, March 9th will be paid a dividend of $0.8937 per share on Tuesday, April 24th. This represents a yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. This is an increase from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire (NASDAQ:SHPG) announced its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, beating the Zacks' consensus estimate of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a net margin of 28.96% and a return on equity of 13.60%. The company's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the business earned $3.63 EPS. View Shire's Earnings History.

When is Shire's next earnings date?

Shire is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Shire.

What guidance has Shire issued on next quarter's earnings?

Shire updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus estimate of $15.23. The company issued revenue guidance of $15.4-15.9 billion, compared to the consensus revenue estimate of $15.48 billion.

What price target have analysts set for SHPG?

17 brokers have issued 12 month price objectives for Shire's shares. Their forecasts range from $150.00 to $245.00. On average, they anticipate Shire's stock price to reach $201.6429 in the next year. View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:
  • 1. According to Zacks Investment Research, "Sales of Shire’s Mydayis showed promise in the first six months of launch. Also, strong performance of Vyvanse, Cinryze and Elaprase continue to drive its top line. The label expansion of Firazyr in pediatrics and approval of Lyophilized Oncaspar in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. Though the adult ADHD space is one of the largest and fastest growing segments of the market, it is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past year. Estimates movement remains mixed ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2018)
  • 2. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018)
  • 3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)

Are investors shorting Shire?

Shire saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 1,486,913 shares, an increase of 110.7% from the April 13th total of 705,730 shares. Based on an average daily trading volume, of 2,705,597 shares, the short-interest ratio is presently 0.5 days. Approximately 0.5% of the company's shares are sold short.

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Prof. Andreas Busch Ph.D., Head of R&D & Chief Scientific Officer (Age 55)

Has Shire been receiving favorable news coverage?

Media stories about SHPG stock have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Shire earned a media sentiment score of 0.19 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Shire's major shareholders?

Shire's stock is owned by many different of retail and institutional investors. Top institutional shareholders include The Manufacturers Life Insurance Company (0.61%), Northern Trust Corp (0.34%), BlackRock Inc. (0.30%), Rockefeller Capital Management L.P. (0.25%), New South Capital Management Inc. (0.22%) and Delek Group Ltd. (0.08%). View Institutional Ownership Trends for Shire.

Which institutional investors are selling Shire stock?

SHPG stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Point72 Asset Management L.P., MD Sass Investors Services Inc., BlackRock Inc., Guggenheim Capital LLC, PNC Financial Services Group Inc., Van ECK Associates Corp and Eagle Global Advisors LLC. View Insider Buying and Selling for Shire.

Which institutional investors are buying Shire stock?

SHPG stock was purchased by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Prosight Management LP, Delek Group Ltd., Sphera Funds Management LTD., Dimensional Fund Advisors LP, First Light Asset Management LLC, Forsta AP Fonden and Sector Gamma AS. View Insider Buying and Selling for Shire.

How do I buy shares of Shire?

Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $169.89.

How big of a company is Shire?

Shire has a market capitalization of $51.55 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]


MarketBeat Community Rating for Shire (SHPG)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  929 (Vote Outperform)
Underperform Votes:  463 (Vote Underperform)
Total Votes:  1,392
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire (NASDAQ:SHPG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
17 Wall Street analysts have issued ratings and price targets for Shire in the last 12 months. Their average twelve-month price target is $201.6429, suggesting that the stock has a possible upside of 18.69%. The high price target for SHPG is $245.00 and the low price target for SHPG is $150.00. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.692.712.63
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $201.6429$205.00$204.00$212.1818
Price Target Upside: 18.69% upside27.50% upside61.05% upside51.53% upside

Shire (NASDAQ:SHPG) Consensus Price Target History

Price Target History for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018Kepler Capital MarketsReiterated RatingBuy ➝ BuyLowView Rating Details
5/8/2018Royal Bank of CanadaReiterated RatingBuyLowView Rating Details
4/29/2018BTIG ResearchReiterated RatingBuy$195.00LowView Rating Details
4/19/2018B. RileyBoost Price TargetBuy$200.00LowView Rating Details
4/16/2018Cantor FitzgeraldSet Price TargetBuy$222.00MediumView Rating Details
3/28/2018Bank of AmericaReiterated RatingBuyHighView Rating Details
2/20/2018SunTrust BanksLower Price TargetBuy$190.00MediumView Rating Details
2/20/2018JPMorgan ChaseReiterated RatingOverweight ➝ NeutralMediumView Rating Details
2/14/2018Sanford C. BernsteinUpgradeMarket Perform ➝ OutperformMediumView Rating Details
1/5/2018CowenSet Price TargetBuy$225.00LowView Rating Details
1/3/2018Piper Jaffray CompaniesReiterated RatingHoldLowView Rating Details
12/20/2017Liberum CapitalReiterated RatingBuy ➝ HoldMediumView Rating Details
10/30/2017FBR & CoReiterated RatingBuy$201.00N/AView Rating Details
10/8/2017Stifel NicolausReiterated RatingBuy$245.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$196.00MediumView Rating Details
8/11/2017BarclaysDowngradeOverweight ➝ Equal WeightLowView Rating Details
8/9/2017Jefferies GroupReiterated RatingHold$216.00 ➝ $206.00LowView Rating Details
4/17/2017Goldman SachsBoost Price TargetOverweight$202.00 ➝ $214.00LowView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/6/2016UBSDowngradeBuy ➝ HoldN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/3/2016CitigroupReiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Shire (NASDAQ:SHPG) Earnings History and Estimates Chart

Earnings by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Earnings Estimates

2018 EPS Consensus Estimate: $15.38
2019 EPS Consensus Estimate: $15.58
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$3.54$4.01$3.81
Q2 20186$3.64$3.97$3.76
Q3 20186$3.64$4.08$3.81
Q4 20186$3.78$4.37$4.00
Q1 20192$3.58$3.93$3.76
Q2 20192$3.73$3.99$3.86
Q3 20192$3.77$3.95$3.86
Q4 20192$3.98$4.23$4.11

Shire (NASDAQ SHPG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018        
4/26/20183/31/2018$3.58$3.86$3.7657 billionViewN/AView Earnings Details
2/14/2018n/a$3.86$3.98$4.1449 billionViewN/AView Earnings Details
10/27/20179/30/2017$3.64$3.81$3.6976 billionViewN/AView Earnings Details
8/3/20176/30/2017$3.53$3.73$3.7458 billionViewListenView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.5723 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.7752 billion$3.8061 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.2757 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.0540$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.7160 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.5293 billion$1.5761 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.2146 billion$1.2750 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
10/29/2010Q3 2010$0.98$1.16ViewN/AView Earnings Details
8/4/2010Q2 2010$0.88$1.03ViewN/AView Earnings Details
4/29/2010Q1 2010$0.84$1.01ViewN/AView Earnings Details
2/19/2010Q4 2009$0.58$1.10ViewN/AView Earnings Details
10/30/2009Q3 2009$0.48$0.49ViewN/AView Earnings Details
8/5/2009Q2 2009$0.47$0.60ViewN/AView Earnings Details
4/30/2009Q1 2009$1.08$1.28ViewN/AView Earnings Details
2/19/2009Q4 2008$1.00$1.01ViewN/AView Earnings Details
10/29/2008Q3 2008$0.87$1.17ViewN/AView Earnings Details
7/31/2008Q2 2008$0.75$0.95ViewN/AView Earnings Details
4/25/2008Q1 2008$0.72$0.74ViewN/AView Earnings Details
2/21/2008Q4 2007$0.64$0.94ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Shire (NASDAQ:SHPG) Dividend Information

Shire pays an annual dividend of $1.05 per share, with a dividend yield of 0.62%. SHPG's most recent semiannual dividend payment was Tuesday, April 24. Shire pays out 6.93% of its earnings out as a dividend.
Most Recent Dividend:4/24/2018
Annual Dividend:$1.05
Dividend Yield:0.62%
Payout Ratio(s):6.93% (Trailing 12 Months of Earnings)
6.88% (Based on This Year's Estimates)
6.48% (Based on Next Year's Estimates)
4.62% (Based on Cash Flow)
Dividend Payments by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/16/2018semiannual$0.89371.33%3/8/20183/9/20184/24/2018
8/11/2017semiannual$0.15270.21%9/7/20179/8/201710/20/2017
2/24/2017$0.77103/8/20173/10/20174/25/2017
8/5/2016$0.13909/7/20169/9/201610/7/2016
2/11/2016$0.66503/9/20163/11/20164/12/2016
7/23/2015$0.12639/2/20159/4/201510/2/2015
2/23/2015semiannual$0.57270.48%3/11/20153/13/20154/14/2015
8/4/2014semiannual$0.11490.09%9/3/20149/5/201410/3/2014
2/20/2014semiannual$0.50790.61%3/5/20143/7/20144/8/2014
7/29/2013semiannual$0.090.16%9/4/20139/6/201310/3/2013
2/19/2013semiannual$0.43800.92%3/6/20133/8/20134/9/2013
(Data available from 1/1/2013 forward)

Insider Trades

Shire (NASDAQ SHPG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 18.12%
Insider Trading History for Shire (NASDAQ:SHPG)
Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ SHPG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Shire (NASDAQ SHPG) News Headlines

Source:
DateHeadline
SHIRE RELEASES DATA AT THE WFH CONGRESS 2018 EVALUATING VONVENDI® IN ADULTS WITH VON ...SHIRE RELEASES DATA AT THE WFH CONGRESS 2018 EVALUATING VONVENDI® IN ADULTS WITH VON ...
globenewswire.com - May 22 at 8:16 AM
Shire (SHPG) Receives Average Rating of "Buy" from AnalystsShire (SHPG) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 20 at 1:41 PM
FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire dealFOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal
finance.yahoo.com - May 17 at 8:17 AM
Takeda CEO prescribes surgical R&D cuts after $62 billion Shire dealTakeda CEO prescribes surgical R&D cuts after $62 billion Shire deal
finance.yahoo.com - May 17 at 8:17 AM
Shire plc: Rule 2.9 AnnouncementShire plc: Rule 2.9 Announcement
finance.yahoo.com - May 16 at 8:15 AM
Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing ...Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing ...
www.prnewswire.com - May 15 at 8:21 AM
Shire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases AwarenessShire Recognizes MPS Awareness Day 2018 with Digital Campaign and Global Events Focused on Increasing Diseases Awareness
finance.yahoo.com - May 15 at 8:21 AM
$3.81 Billion in Sales Expected for Shire (SHPG) This Quarter$3.81 Billion in Sales Expected for Shire (SHPG) This Quarter
www.americanbankingnews.com - May 15 at 4:59 AM
Takeda and Shire: A Pricey MarriageTakeda and Shire: A Pricey Marriage
www.fool.com - May 14 at 6:35 PM
Q2 2018 EPS Estimates for Shire Boosted by Analyst (SHPG)Q2 2018 EPS Estimates for Shire Boosted by Analyst (SHPG)
www.americanbankingnews.com - May 14 at 1:43 AM
Shire (SHPG) Short Interest Up 110.7% in AprilShire (SHPG) Short Interest Up 110.7% in April
www.americanbankingnews.com - May 13 at 1:40 AM
Zacks: Brokerages Anticipate Shire (SHPG) to Post $3.69 EPSZacks: Brokerages Anticipate Shire (SHPG) to Post $3.69 EPS
www.americanbankingnews.com - May 13 at 1:20 AM
Shire (SHPG) Coverage Initiated by Analysts at Kepler Capital MarketsShire (SHPG) Coverage Initiated by Analysts at Kepler Capital Markets
www.americanbankingnews.com - May 11 at 9:19 PM
Takeda Pharmaceuticals (TKPHF) CEO Christophe Weber on the Proposed Acquisition of Shire PLC Group (Transcript)Takeda Pharmaceutical's (TKPHF) CEO Christophe Weber on the Proposed Acquisition of Shire PLC Group (Transcript)
seekingalpha.com - May 11 at 6:03 PM
Whisky and Apologies Aided Takedas $62 Billion Shire GambleWhisky and Apologies Aided Takeda's $62 Billion Shire Gamble
www.bloomberg.com - May 11 at 8:18 AM
Iconic Genzyme building faces uncertain future after Shire-Takeda dealIconic Genzyme building faces uncertain future after Shire-Takeda deal
finance.yahoo.com - May 11 at 8:18 AM
Takeda Shareholders Should Come Around to ShireTakeda Shareholders Should Come Around to Shire
finance.yahoo.com - May 10 at 8:19 AM
Takeda Pharmaceutical Company Limited -- Moodys downgrades Takeda Pharmaceutical to A2; places ratings on review for further downgradeTakeda Pharmaceutical Company Limited -- Moody's downgrades Takeda Pharmaceutical to A2; places ratings on review for further downgrade
finance.yahoo.com - May 9 at 8:15 AM
Takeda Near Deal to Buy Shire (SHPG) for $64 Billion - BloombergTakeda Near Deal to Buy Shire (SHPG) for $64 Billion - Bloomberg
www.streetinsider.com - May 8 at 5:45 PM
Royal Bank of Canada Reiterates Buy Rating for Shire (SHPG)Royal Bank of Canada Reiterates Buy Rating for Shire (SHPG)
www.americanbankingnews.com - May 8 at 10:22 AM
Iran Day, Takeda and Shire, Athenahealth Bid: CEO Daily for May 8, 2018Iran Day, Takeda and Shire, Athenahealth Bid: CEO Daily for May 8, 2018
fortune.com - May 8 at 8:12 AM
Takeda Clinches $62 Billion Deal to Buy Drugmaker ShireTakeda Clinches $62 Billion Deal to Buy Drugmaker Shire
www.bloomberg.com - May 8 at 8:12 AM
Japans Takeda agrees $62 billion takeover of ShireJapan's Takeda agrees $62 billion takeover of Shire
www.reuters.com - May 8 at 8:12 AM
Shire rally pushes FTSE 100 to 14-week highShire rally pushes FTSE 100 to 14-week high
www.marketwatch.com - May 8 at 8:12 AM
Blog Exposure - FDA Granted Fast Track Designation for REGENXBIOs RGX-121 Gene Therapy for Mucopolysaccharidosis Type IIBlog Exposure - FDA Granted Fast Track Designation for REGENXBIO's RGX-121 Gene Therapy for Mucopolysaccharidosis Type II
finance.yahoo.com - May 4 at 8:15 AM
Shire (SHPG) Rating Lowered to Sell at ValuEngineShire (SHPG) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - May 2 at 6:02 PM
FY2018 EPS Estimates for Shire Lifted by Analyst (SHPG)FY2018 EPS Estimates for Shire Lifted by Analyst (SHPG)
www.americanbankingnews.com - May 2 at 9:26 AM
Shire plc : Form 8 (DD) - Thomas DittrichShire plc : Form 8 (DD) - Thomas Dittrich
globenewswire.com - May 2 at 8:18 AM
The Takeda-Shire Deal: Potential Impact On NeuroscienceThe Takeda-Shire Deal: Potential Impact On Neuroscience
seekingalpha.com - May 1 at 8:19 AM
Shire plc : Total voting rightsShire plc : Total voting rights
finance.yahoo.com - May 1 at 8:19 AM
Shire plc : Form 8 (DD) - Flemming OrnskovShire plc : Form 8 (DD) - Flemming Ornskov
finance.yahoo.com - May 1 at 8:19 AM
What Analysts Recommend for BioMarin Pharmaceutical in April 2018What Analysts Recommend for BioMarin Pharmaceutical in April 2018
finance.yahoo.com - April 30 at 8:18 AM
Q2 2018 Earnings Estimate for Shire Issued By B. Riley (SHPG)Q2 2018 Earnings Estimate for Shire Issued By B. Riley (SHPG)
www.americanbankingnews.com - April 30 at 1:28 AM
Analysts Issue Forecasts for Shires Q2 2018 Earnings (SHPG)Analysts Issue Forecasts for Shire's Q2 2018 Earnings (SHPG)
www.americanbankingnews.com - April 30 at 1:25 AM
Shire to Post Q2 2018 Earnings of $3.80 Per Share, Piper Jaffray Forecasts (SHPG)Shire to Post Q2 2018 Earnings of $3.80 Per Share, Piper Jaffray Forecasts (SHPG)
www.americanbankingnews.com - April 30 at 1:25 AM
Shires (SHPG) Buy Rating Reiterated at BTIG ResearchShire's (SHPG) Buy Rating Reiterated at BTIG Research
www.americanbankingnews.com - April 29 at 9:17 AM
Once-bitten merger arbitrageurs are twice ShireOnce-bitten merger arbitrageurs are twice Shire
www.nasdaq.com - April 27 at 8:26 AM
Shire Sales Exceed Estimates, Potentially Calming Deal ConcernsShire Sales Exceed Estimates, Potentially Calming Deal Concerns
www.bloomberg.com - April 27 at 8:26 AM
Shire: Were Earnings Good Enough To Warrant Takeover Talk?Shire: Were Earnings Good Enough To Warrant Takeover Talk?
seekingalpha.com - April 27 at 8:26 AM
Short Interest in Shire (SHPG) Declines By 69.4%Short Interest in Shire (SHPG) Declines By 69.4%
www.americanbankingnews.com - April 27 at 3:42 AM
Zacks: Analysts Expect Shire (SHPG) Will Announce Quarterly Sales of $3.78 BillionZacks: Analysts Expect Shire (SHPG) Will Announce Quarterly Sales of $3.78 Billion
www.americanbankingnews.com - April 27 at 2:56 AM
Shire (SHPG) Posts Quarterly  Earnings Results, Beats Expectations By $0.28 EPSShire (SHPG) Posts Quarterly Earnings Results, Beats Expectations By $0.28 EPS
www.americanbankingnews.com - April 26 at 6:32 PM
Shire (SHPG) Issues FY18 Earnings GuidanceShire (SHPG) Issues FY18 Earnings Guidance
www.americanbankingnews.com - April 26 at 9:26 AM
Shire profit rises on higher sales, backs outlookShire profit rises on higher sales, backs outlook
www.marketwatch.com - April 26 at 8:13 AM
Bid target Shire grows earnings six percent, holds cautious outlookBid target Shire grows earnings six percent, holds cautious outlook
finance.yahoo.com - April 26 at 8:13 AM
[$$] Shire Q1 sales rise 7% driven by immunology and new treatments[$$] Shire Q1 sales rise 7% driven by immunology and new treatments
finance.yahoo.com - April 26 at 8:13 AM
Shire plc : 1st Quarter ResultsShire plc : 1st Quarter Results
feeds.benzinga.com - April 26 at 7:57 AM
Traders Buy High Volume of Shire Put Options (SHPG)Traders Buy High Volume of Shire Put Options (SHPG)
www.americanbankingnews.com - April 26 at 6:34 AM
Shire (SHPG) Receives Average Recommendation of "Buy" from BrokeragesShire (SHPG) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 25 at 1:36 PM
Shire (SHPG) Expected to Announce Earnings of $3.58 Per ShareShire (SHPG) Expected to Announce Earnings of $3.58 Per Share
www.americanbankingnews.com - April 25 at 1:24 PM

SEC Filings

Shire (NASDAQ:SHPG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Shire (NASDAQ:SHPG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Shire (NASDAQ SHPG) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.